Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with PURA gene mutation. In a further embodiment the types of seizures include tonic, atonic and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with SYNGAP1 gene mutation. In a further embodiment the types of seizures include atonic and absence seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are experienced in patients diagnosed with Cortical Dysplasia and Cortical Brain Malformation. In a further embodiment the types of seizures include atonic, tonic, and focal without impairment seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) with DEPDC5 gene mutation. In a further embodiment the types of seizures include tonic, tonic-clonic and focal seizures without impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with mutation in the potassium channel (KCN) gene. In a further embodiment the types of seizures include tonic, tonic-clonic, absence and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with BRAF mutation. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with mutations on GR1N2B and CACNA1H genes. In a further embodiment the types of seizures include tonic-clonic, absence and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with GPHN mutation. In a further embodiment the types of seizures include tonic and tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with gross chromosomal mutations including 15q11.2 deletion; 1p36 deletion; 22Q11 duplication; 9p21.1 deletion with autistic spectrum disorder; monosomy 16p13.3 and trisomy 2p25.3; chromosome 3q duplication; and trisomy 13. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, absence, focal seizures without impairment, focal seizures with impairment and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with Rett syndrome. In a further embodiment the types of seizures include tonic, tonic-clonic, absence seizures and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with congenital disorder of glycosylation 1P. In a further embodiment the types of seizures include tonic and myoclonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present disclosure provides a capture assembly optionally for use in an automated sample analyzer. The sample analyzer includes an optical assembly for scanning a sample well of a planar substrate, e.g., a multiwell plate that is loaded onto and secured to the capture assembly to perform an assay, e.g., detection of an analyte in the sample. The capture assembly automatically aligns the planar substrate about a rotational axis of a drive shaft and secures the substrate to the drive shaft to prevent unwanted movement or slippage of the substrate during starting, stopping and rotation of the substrate at varying rotational velocities thereby ensuring the sample well is reliably detected by the optical assembly.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with ZDHHC9 gene mutation. In a further embodiment the types of seizures include tonic-clonic and atonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with CLCN4 gene mutation. In a further embodiment the types of seizures include tonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with CHRNA4 gene mutation. In a further embodiment the types of seizures include tonic-clonic, atonic, myoclonic and absence seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: A near-range camera assembly for a vehicle is provided. The near-range camera assembly includes a LIDAR mount couplable to a vehicle. The LIDAR mount includes a first surface and a second surface that opposes the first surface. The near-range camera assembly includes a LIDAR unit removably coupled to the first surface LIDAR mount. The near-range camera assembly further includes a camera and a camera housing for the camera. The camera housing is removably coupled to the second surface LIDAR mount.

Abstract: A mounting assembly for a cabin camera is provided. The mounting assembly includes a camera housing for the camera. The mounting assembly further includes a headliner mount removably coupled to the camera housing. The headliner mount includes a base and one or more retention members hingably coupled to the base. The one or more retention members are movable relative to the base to selectively secure the headliner mount to a headliner of a vehicle.

Abstract: A smart-home device may include a temperature sensor, energy-consuming subsystems, and processors programmed to receive a temperature measurement from the temperature sensor for an ambient environment surrounding the temperature sensor; receive inputs from the energy-consuming subsystems that indicate power-consuming activities of the energy-consuming subsystems; providing the inputs from the energy-consuming subsystems to a model that is trained to calculate an effect of the power-consuming activity of the energy-consuming subsystems on the temperature measurement from the temperature sensor; and calculating an estimate of the temperature of the ambient environment by compensating the temperature measurement from the temperature sensor with using the effect of the power-consuming activity of the energy-consuming subsystems.

Abstract: Systems and methods for reconfiguring seats of an autonomous vehicle is provided. The method includes obtaining service request data that includes a service selection and request characteristics. The method includes obtaining data describing an initial seat configuration for each of a plurality of seats of an autonomous vehicle assigned to the service request. The initial seat configuration can include a seat position and a seat orientation for each of the plurality of seats. The method includes generating, based on the initial cabin configuration and the service request data, seat adjustment instructions configured to adjust the initial seat configuration of at least one of the seats. The method includes providing the seat adjustment instructions to the autonomous vehicle assigned to the service request.